Want to see CNTB full AI Analyst Report?
CNTB Stock Chart & Stats
$2.45
-$0.06(-2.73%)
At close: 4:00 PM EDT
$2.45
-$0.06(-2.73%)
Day’s Range― - ―
52-Week Range$0.89 - $3.82
Previous CloseN/A
Volume327.99K
Average Volume (3M)7.15M
Market Cap
$61.70M
Enterprise Value$118.77
Total Cash (Recent Filing)$31.49M
Total Debt (Recent Filing)$596.00K
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Nov 18, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding62,974,308
10 Day Avg. Volume17,835,284
30 Day Avg. Volume7,153,993
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.74
Price to Sales (P/S)2452.52
P/FCF Ratio-3.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.86Price Target Upside179.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-6.7
Revenue Forecast (FY)$50.28M
Bulls Say, Bears Say
Bulls Say
COPD Phase 2 EfficacyThe COPD results provide meaningful clinical validation for rademikibart in a serious respiratory setting, with lower treatment failure and exacerbations than placebo. If confirmed in later development, this efficacy could support differentiation, regulatory progress, and a broader respiratory franchise.
Asthma Phase 2 ProgressPositive asthma data broaden the program’s potential beyond COPD and demonstrate progress in another type 2 inflammation indication. The statistically significant lung-function improvement and planned Phase 3 path may increase the pipeline’s strategic value if follow-on studies reproduce the benefit.
Low Debt BurdenMinimal debt reduces fixed financing obligations and avoids the added interest and refinancing pressures associated with heavier leverage. This gives Connect more balance-sheet flexibility to direct available resources toward clinical development, although it does not eliminate the need for future funding.
Bears Say
No Recurring Product RevenueThe absence of reported 2025 revenue leaves the company without a durable operating base to offset research and development costs. Substantial losses increase dependence on successful clinical execution and future financing, making earnings quality and visibility weak over the medium term.
Persistent Cash BurnLarge recurring cash outflows mean Connect is consuming capital rather than funding operations internally. Unless spending declines or collaboration and product revenue recover, continued development will require external financing, which can constrain strategy and create dilution or funding risk.
Contracting Capital BaseThe sharp reduction in equity and assets reflects the financial impact of ongoing losses and leaves a smaller resource base supporting the pipeline. Reduced financial flexibility may limit development options and increase the importance of securing capital or productive partnerships.
Connect Biopharma Holdings News
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $0.89 and its highest was $3.82 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $61.70M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is Nov 18, 2026 which is in 46 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on Aug 12, 2026. The company reported -$0.272 earnings per share for the quarter, beating the consensus estimate of -$0.319 by $0.048.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate is -0.26.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 62,974,308 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of -$0.272 in its last earnings report, beating expectations of -$0.319. Following the earnings report the stock price went up 9.013%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Currently, no hedge funds are holding shares in CNTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Connect Biopharma Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.86 (179.88% Upside)
$6.86 (179.88% Upside)
Blogger Sentiment
Bullish
CNTB Sentiment 100%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.1%
Last 30 Days ▲ 28.9%
Last 30 Days ▲ 28.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-47.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
CNTB Stock 12 Month Forecast
Average Price Target
$6.86
▲(179.88% Upside)
Technical Analysis
Scinai Immunotherapeutics
―
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Ownership Overview
21.31% Insiders
0.04% Mutual Funds
16.28% Other Institutional Investors
61.13% Public Companies and
Individual Investors